Welcome to our dedicated page for Renovacare news (Ticker: RCAR), a resource for investors and traders seeking the latest updates and insights on Renovacare stock.
RenovaCare, Inc. (RCAR) generates news primarily through developments in its cell-based regenerative medicine programs, regulatory milestones, legal proceedings, and corporate actions. The company describes itself as a clinical-stage developer of patented technologies such as the CellMist™ System and SkinGun™ spray device, designed to apply a patient’s own stem cells to burns and other wounds. News coverage often highlights progress or changes in these programs and the broader context of its research and development activities.
One category of RenovaCare news involves clinical and regulatory updates. The company has announced full FDA Investigational Device Exemption (IDE) approval for its SkinGun™ and CellMist™ System, enabling the CELLMIST 1 (CELLMIST-1) clinical trial in adult burn patients. Subsequent releases have provided updates on trial activation, patient screening at burn centers, and later suspension of patient enrollment due to factors including COVID-19-related low enrollment and funding constraints.
Another recurring theme in RenovaCare news is its intellectual property and technology platform. The company has reported new patents for its SkinGun™ device and cell isolation technologies, expansion of its patent portfolio across multiple jurisdictions, and statements about potential applications in cell therapies, biologics, and drug delivery. These announcements offer insight into how RenovaCare positions its technology and protects its developments.
RenovaCare’s news flow also includes corporate and legal disclosures. Press releases detail organizational and management changes, cost-cutting measures, and responses to a civil complaint filed by the U.S. Securities and Exchange Commission, along with related class action and derivative lawsuits. More recent communications describe a proposed derivative settlement involving debt cancellation and planned governance reforms tied to the composition and independence of the company’s Board of Directors.
Investors and observers reviewing the RCAR news page can expect a mix of clinical trial updates, patent and technology announcements, governance and management changes, and information about ongoing legal matters. Together, these items provide context on RenovaCare’s development-stage activities, regulatory interactions, and corporate governance environment over time.
RenovaCare, a clinical-stage developer, announced its participation in the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10. The company will showcase its patented technologies, CellMist™ and SkinGun™, aimed at regenerating skin and other tissues using self-donated stem cells. An on-demand webcast will be available for registered attendees, including institutional investors and industry executives. RenovaCare focuses on innovative stem cell therapies for skin regeneration, with R&D centered in Berlin, Germany.
RenovaCare, Inc. (RCAR) announced that Alan L. Rubino has been elected as Chairman of the Board, effective October 1, 2020. He replaces Harmel S. Rayat, who resigned from the position. Rubino has served as CEO and President since November 2019 and is tasked with transitioning the company from pre-clinical to a developmental stage entity. Rayat expressed confidence in Rubino and his management team, emphasizing their capabilities and commitment to advancing RenovaCare's regenerative technology, including the CellMist™ System for treating burns and wounds.